Resumen
Aims Systematically reviewing the literature found orthostatic hypotension (OH) to be associated with an increased risk of incident dementia but limited data were available in those at highest risk, the hypertensive oldest-old. Our aim was to analyse the relationship between OH and incident cognitive decline or dementia in this group and to synthesize the evidence base overall. Method and results Participants aged ≥80 years, with hypertension, were from the Hypertension in the Very Elderly Trial (HYVET) cohort. Orthostatic hypotension was defined as a fall of ≥15mmHg in systolic and or ≥7mmHg in diastolic pressure after 2 min standing from a sitting position. Subclinical orthostatic hypotension with symptoms (SOH) was defined as a fall <OH but with unsteadiness, light-headedness, or faintness in the week before blood pressure measurement. Proportional hazard regression was used to examine the relationship between baseline OH, SOH, and cognitive outcomes. There were 3121 in the analytical sample, 538 with OH. Orthostatic hypotension was associated with increased risk of cognitive decline (906 events), hazard ratio (HR) 1.36 (95% confidence interval 1.14-1.59). For incident dementia (241 events), HR 1.34 (0.98-1.84). When competing risk of cardiovascular events were taken into account results were HR 1.39 (1.19-1.62) and HR 1.34 (1.05-1.73), respectively. Subclinical orthostatic hypotension was associated with an increased risk of cognitive decline HR 1.56 (1.12-2.17) and dementia HR 1.79 (1.00-3.20). Combining the results from the HYVET cohort in a meta-analysis with the existing published literature in this area found a 21% (9-35%) increased risk of dementia with OH. Conclusion Orthostatic hypotension indicates an increased risk of dementia and cognitive decline. SOH may also be considered a risk factor, at least in older hypertensive adults. Questions remain regarding the mechanisms and whether interventions to reduce impact of OH could protect cognition.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 3135-3143 |
Número de páginas | 9 |
Publicación | European Heart Journal |
Volumen | 39 |
N.º | 33 |
DOI | |
Estado | Published - sep. 1 2018 |
Nota bibliográfica
Funding Information:This work was not supported by a particular funding body. R.P. is funded by the Australian Dementia Collaborative Research Centre. K.J.A. is funded by National Institute of Health and Medical Research (NHMRC) Fellowship APP1102694. A.B.’s literature search and methodological input was undertaken under his University of Sheffield employment contract. He has no financial conflicts of interest. K.R. is funded through the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer’s Research and receives research funding from the Canadian Institutes of Health Research, the Canadian Frailty Network and the Fountain Family Research Fund of the Queen Elizabeth II Health Sciences Centre. The HYVET trial was funded by academic grants from the British Heart Foundation and Servier International to Imperial College London. Funding bodies had no role in the inception, design, completion, or publication of this work.
Publisher Copyright:
© 2018 The Royal Society of Chemistry.
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine